Sandoz launches authorized generic version of Tobi®

Princeton, New Jersey, July 14, 2014 – Sandoz today announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI®, currently marketed by Novartis Pharmaceuticals Corporation1.

Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa.

Cystic fibrosis is a life-threatening genetic disease that primarily affects the lungs and digestive system. An estimated 30,000 children and adults in the United States (70,000 …

/by

Novartis maintained strong innovation momentum in second quarter, while reconfirming full year outlook

Basel, July 17, 2014 – Commenting on the results, Joseph Jimenez, CEO of Novartis, said: “Novartis delivered solid financial performance with core margin expansion in the second quarter and first half. Pharmaceuticals, in particular, showed improved productivity, driving core operating leverage for the Group. We also made significant progress on innovation across the portfolio, reaching milestones such as FDA approval for Zykadia in ALK+ non-small cell lung cancer, FDA Fast Track designation and rolling submission for LCZ696 in chronic heart failure, CHMP recommendation …

/by

Sandoz’s Joerg Windisch reelected as chair of Ega’s European biosimilars group

Today, Sandoz announced that the European Generic medicines Agency (EGA) has reelected Dr. Joerg Windisch, Chief Science Officer at Sandoz, as chair of its European Biosimilars Group (EBG).

Read more

/by

Sandoz brings together key French stakeholders to discuss biosimilars

Sandoz, the global leader in biosimilars, recently hosted an event in Paris for key stakeholders to discuss strategic issues impacting biosimilars and help them better understand their vital role in the success of these important therapies in France.

Read more

/by

Sandoz launches authorized generic version of Diovan® in the US

Princeton, New Jersey, July 8, 2014 – Sandoz today announced the US introduction of an authorized generic version of Diovan® (valsartan) tablets for the treatment of high blood pressure (HBP).

​This launch follows the Sandoz US introduction of an authorized generic version of Diovan HCT® (valsartan and hydrochlorothiazide) in 2012. Both Diovan and Diovan HCT are marketed in the US by Novartis Pharmaceuticals Corporation (NPC) and are indicated for the treatment of HBP, a condition that affects approximately one in three US adults.1,2

“We are pleased to offer …

/by

Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide

  • Sandoz makes long-term commitment to support UN initiative on child mortality
  • Commitment to UN Every Newborn Action Plan involves development and supply of recommended WHO formulation for treating childhood pneumonia
  • Pneumonia is the leading cause of death globally among children under five

Holzkirchen, June 30, 2014 – Sandoz today announces a long-term commitment to help prevent the deaths of millions of children worldwide by supplying a key antibiotic formulation, as part of the United Nations’ new Every Newborn Action Plan.

The …

/by

Sandoz launches Airflusal® Forspiro® in Sweden, further driving patient access to innovative new respiratory inhaler

  • Sweden is fourth European country to launch Sandoz’s award-winning new inhaler for patients with asthma and COPD
  • Sandoz Sweden launches both 50-500 and 50-250 microgram dosage forms, following national marketing authorization earlier this year
  • Airflusal Forspiro offers proven combination of salmeterol and fluticasone propionate in an innovative new device, co-developed with patients

Holzkirchen, June 23, 2014: Sandoz today announced the launch in Sweden of Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or …

/by

Sandoz launches three new products in Japan, including authorized generics of valsartan and zoledronic acid

  • Sandoz Japan launches valsartan, the first authorized generic ARB in Japan. Sandoz also launches authorized generic of Zometa® for i.v. infusion 4mg/5mL and generic version of Preminent® Tablets LD

Tokyo, June 20, 2014 Sandoz announces today the launch in Japan of three new products, including valsartan, a generic version of Novartis’ Diovan® Tablets, zoledronic acid, a generic version of Novartis’ Zometa® for i.v. infusion 4mg/5mL and Losarhyd (losartan potassium/hydrochlorothiazide), a generic version of MSD’s Preminent® Tablets LD.

Valsartan and …

/by

GSK application for preliminary injunction withdrawn just before Cologne Court of appeals was to rule in the case

  • GlaxoSmithKline withdraws application for preliminary injunction on German marketing and distribution of Sandoz’s award-winning AirFluSal® Forspiro®
  • GSK application withdrawn shortly before Cologne Court of Appeals was due to rule in the case, restoring German patient access to AirFluSal
  • Sandoz continues to roll out its innovative and cost-effective respiratory inhaler, co-developed with patients, in Europe and beyond

Holzkirchen, June 16, 2014: Pharmaceutical company GlaxoSmithKline has withdrawn its application for a preliminary …

/by

Sandoz France launches generic Nasonex® nasal spray, the first generic nasal corticoid on the French market

  • French launch is latest milestone in roll-out of Sandoz respiratory portfolio – a key pillar of its strategy to bring differentiated generics to patients and payors worldwide
  • Mometasone Sandoz® is first French specialty generic medicine indicated for treatment of a respiratory condition together with an inhaler
  • Allergic rhinitis affects up to 25% of the population of Western Europe annually

Levallois-Perret, June 2, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz®, …

/by